Archive — US — techcrunch
Level Zero Health banks $6.9M to prove wearable medtech can take the strain outof hormone testing
Level Zero Health has secured $6.9M in pre-seed funding to develop a non-invasive device for continuous hormone monitoring. Founded by women, the startup aims to revolutionize hormone testing, eliminating blood draws and creating a new product category similar to continuous glucose monitors (CGMs). Their first product, a single-use patch for intermittent testing, is set for market entry next year, with a long-term goal of continuous monitoring by 2028.
Key points
- Level Zero Health closed a $6.9M pre-seed funding round to create a continuous hormone monitoring device.
- The startup is focused on a non-invasive solution to replace blood draws for hormone testing, facilitating research on hormone-related conditions.
- Their initial product, a single-use patch for intermittent hormone monitoring, aims for FDA and CE approval next year.
- The patch's goal is to provide a 90%+ correlation with traditional blood tests, enhancing accuracy in hormone level monitoring.
- Long-term plans include a continuous monitoring device set for release in 2028, leveraging interstitial fluid data.
Why it matters
- The rise of personalized medicine trends in healthcare aligns with innovations like CGMs, which transformed diabetes care.
- A growing focus on women's health technology reflects shifting investment dynamics within the medtech industry.
- Prior advances in biosensor technology highlight a trend toward less invasive health monitoring solutions.
Level Zero Health's innovative approach to hormone monitoring could significantly enhance personalized healthcare, similar to the success of continuous glucose monitors, paving the way for a new frontier in health diagnostics.